Boston Scientific Corp (BSX) stock
BSXNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 14/3055% below fair value
$41.98−0.71 (-1.66%)
Close on Oct 30, 2026Market cap $60.84BP/E 17.0Yield –
Earnings
Boston Scientific's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Feb 3, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$5.14B
+1.4% on a year earlier
adjusted EPS, Q3 FY2026
$0.73
$0.75 a year earlier
Latest guidance
Issued
Oct 28, 2026 · 6 items
Quarterly results
Revenue and earnings per share from each of Boston Scientific's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 3, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Oct 28, 2026before the open | $5.14B | +1.4% | $0.40 | $0.73 | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 29, 2026before the open | $5.44B | +7.5% | $0.61 | $0.86 | Release |
| Q1 FY2026ended Mar 31, 2026 | Apr 22, 2026before the open | $5.20B | +11.6% | $0.90 | $0.80 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 4, 2026before the open | $5.29B | +15.9% | $0.45 | $0.80 | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 22, 2025before the open | $5.07B | +20.3% | $0.51 | $0.75 | Release |
| Q2 FY2025ended Jun 30, 2025 | Jul 23, 2025before the open | $5.06B | +22.8% | $0.53 | $0.75 | Release |
| Q1 FY2025ended Mar 31, 2025 | Apr 23, 2025before the open | $4.66B | +20.9% | $0.45 | $0.75 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 5, 2025before the open | $4.56B | +22.4% | $0.38 | $0.70 | Release |
| Q3 FY2024ended Sep 30, 2024 | Oct 23, 2024before the open | $4.21B | +19.3% | $0.32 | $0.63 | Release |
| Q2 FY2024ended Jun 30, 2024 | Jul 24, 2024before the open | $4.12B | +14.5% | $0.22 | $0.62 | Release |
| Q1 FY2024ended Mar 31, 2024 | Apr 24, 2024before the open | $3.86B | +13.8% | $0.33 | $0.56 | Release |
| Q4 FY2023ended Dec 31, 2023 | Jan 31, 2024before the open | $3.73B | +14.9% | $0.34 | $0.55 | Release |
| Q3 FY2023ended Sep 30, 2023 | Oct 26, 2023before the open | $3.53B | +11.3% | $0.34 | $0.50 | Release |
| Q2 FY2023ended Jun 30, 2023 | Jul 27, 2023before the open | $3.60B | +10.9% | $0.18 | $0.53 | Release |
| Q1 FY2023ended Mar 31, 2023 | Apr 26, 2023before the open | $3.39B | +12.0% | $0.21 | $0.47 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 1, 2023before the open | $3.24B | +3.7% | $0.09 | $0.45 | Release |
| Q3 FY2022ended Sep 30, 2022 | Oct 26, 2022before the open | $3.17B | +8.1% | $0.12 | $0.43 | Release |
| Q2 FY2022ended Jun 30, 2022 | Jul 27, 2022before the open | $3.24B | – | $0.17 | $0.44 | Release |
| Q1 FY2022ended Mar 31, 2022 | Apr 27, 2022before the open | $3.03B | – | $0.07 | $0.39 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 2, 2022before the open | $3.13B | – | $0.06 | $0.45 | Release |
| Q3 FY2021ended Sep 30, 2021 | Oct 27, 2021before the open | $2.93B | – | $0.28 | $0.41 | Release |
| Q2 FY2021ended Jun 30, 2021 | Jul 27, 2021before the open | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 28, 2021before the open | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 3, 2021before the open | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Oct 28, 2020before the open | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Boston Scientific's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| net salesGAAP | Q4 FY2026 | -3% – -1% | – | New | Oct 28, 2026 |
| net salesnon-GAAP | Q4 FY2026 | -3% – -1% | – | New | Oct 28, 2026 |
| adjusted EPSnon-GAAP | Q4 FY2026 | $0.77 – $0.79 | – | New | Oct 28, 2026 |
| net sales growthGAAP | FY2026 | +4.25% | – | New | Oct 28, 2026 |
| net sales growthnon-GAAP | FY2026 | +3.75% | – | New | Oct 28, 2026 |
| net sales growthGAAP | FY2026 | +5.5% – +6.5% | +7% – +8.5% | Lowered | Jul 29, 2026 |
| organic net sales guidancenon-GAAP | FY2026 | +5% – +6% | +6.5% – +8% | Lowered | Jul 29, 2026 |
| adjusted EPSnon-GAAP | FY2026 | $3.16 – $3.18 | – | New | Oct 28, 2026 |
| adjusted EPSnon-GAAP | FY2026 | $3.28 – $3.32 | $3.34 – $3.41 | Lowered | Jul 29, 2026 |
Guidance vs results
The last range Boston Scientific gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| Q3 FY2026 | adjusted EPS | $0.80 – $0.82 | $0.73 | Below range |
| Q3 FY2026 | Revenue growth | +3% – +5% | +1.44% | Below range |
| Q2 FY2026 | adjusted EPS | $0.82 – $0.84 | $0.86 | Above range |
| Q2 FY2026 | Revenue growth | +5.5% – +7.5% | +7.53% | Within range |
| Q1 FY2026 | adjusted EPS | $0.78 – $0.80 | $0.80 | Within range |
| Q1 FY2026 | Revenue growth | +10.5% – +12% | +11.58% | Within range |
| FY2025 | adjusted EPS | $3.02 – $3.04 | $3.05Σ4Q | Above range |
| FY2025 | EPS (GAAP) | $1.97 – $2.01 | $1.94Σ4Q | Below range |
| FY2025 | Revenue growth | +20% | +19.88%Σ4Q | Below range |
| Q4 FY2025 | adjusted EPS | $0.77 – $0.79 | $0.80 | Above range |
| Q4 FY2025 | EPS (GAAP) | $0.48 – $0.52 | $0.45 | Below range |
| Q4 FY2025 | Revenue growth | +14.5% – +16.5% | +15.9% | Within range |
| Q3 FY2025 | adjusted EPS | $0.70 – $0.72 | $0.75 | Above range |
| Q3 FY2025 | EPS (GAAP) | $0.44 – $0.46 | $0.51 | Above range |
| Q3 FY2025 | Revenue growth | +17% – +19% | +20.34% | Above range |
| Q2 FY2025 | adjusted EPS | $0.71 – $0.73 | $0.75 | Above range |
| Q2 FY2025 | EPS (GAAP) | $0.45 – $0.47 | $0.53 | Above range |
| Q2 FY2025 | Revenue growth | +17.5% – +19.5% | +22.84% | Above range |
| Q1 FY2025 | adjusted EPS | $0.66 – $0.68 | $0.75 | Above range |
| Q1 FY2025 | EPS (GAAP) | $0.43 – $0.45 | $0.45 | Within range |
| Q1 FY2025 | Revenue growth | +17% – +19% | +20.93% | Above range |
| Q4 FY2024 | adjusted EPS | $0.64 – $0.66 | $0.70 | Above range |
| Q4 FY2024 | EPS (GAAP) | $0.41 – $0.43 | $0.38 | Below range |
| Q4 FY2024 | Revenue growth | +16.5% – +18.5% | +22.44% | Above range |
| Q3 FY2024 | adjusted EPS | $0.57 – $0.59 | $0.63 | Above range |
| Q3 FY2024 | EPS (GAAP) | $0.36 – $0.38 | $0.32 | Below range |
| Q3 FY2024 | Revenue growth | +13% – +15% | +19.34% | Above range |
| Q2 FY2024 | adjusted EPS | $0.57 – $0.59 | $0.62 | Above range |
| Q2 FY2024 | EPS (GAAP) | $0.35 – $0.37 | $0.22 | Below range |
| Q2 FY2024 | Revenue growth | +10.5% – +12.5% | +14.48% | Above range |
| Q1 FY2024 | adjusted EPS | $0.50 – $0.52 | $0.56 | Above range |
| Q1 FY2024 | EPS (GAAP) | $0.29 – $0.31 | $0.33 | Above range |
| Q1 FY2024 | Revenue growth | +7.5% – +9.5% | +13.78% | Above range |
| Q4 FY2023 | adjusted EPS | $0.49 – $0.52 | $0.55 | Above range |
| Q4 FY2023 | EPS (GAAP) | $0.26 – $0.30 | $0.34 | Above range |
| Q4 FY2023 | Revenue growth | +9% – +11% | +14.9% | Above range |
| Q3 FY2023 | adjusted EPS | $0.46 – $0.48 | $0.50 | Above range |
| Q3 FY2023 | EPS (GAAP) | $0.21 – $0.25 | $0.34 | Above range |
| Q3 FY2023 | Revenue growth | +8.5% – +10.5% | +11.26% | Above range |
| Q2 FY2023 | adjusted EPS | $0.48 – $0.50 | $0.53 | Above range |
| Q2 FY2023 | EPS (GAAP) | $0.23 – $0.27 | $0.18 | Below range |
| Q2 FY2023 | Revenue growth | +6.5% – +8.5% | +10.94% | Above range |
| Q1 FY2023 | adjusted EPS | $0.42 – $0.44 | $0.47 | Above range |
| Q1 FY2023 | EPS (GAAP) | $0.23 – $0.26 | $0.21 | Below range |
| Q1 FY2023 | Revenue growth | +3% – +5% | +12% | Above range |
| Q4 FY2022 | adjusted EPS | $0.45 – $0.48 | $0.45 | Within range |
| Q4 FY2022 | EPS (GAAP) | $0.23 – $0.28 | $0.09 | Below range |
| Q4 FY2022 | Revenue growth | +2% – +4% | +3.68% | Within range |
| Q3 FY2022 | adjusted EPS | $0.43 – $0.45 | $0.43 | Within range |
| Q3 FY2022 | EPS (GAAP) | $0.20 – $0.24 | $0.12 | Below range |
| Q3 FY2022 | Revenue growth | +6% – +8% | +8.12% | Above range |
| Q2 FY2022 | adjusted EPS | $0.41 – $0.43 | $0.44 | Above range |
| Q2 FY2022 | EPS (GAAP) | $0.19 – $0.23 | $0.17 | Below range |
| Q1 FY2022 | adjusted EPS | $0.38 – $0.40 | $0.39 | Within range |
| Q1 FY2022 | EPS (GAAP) | $0.16 – $0.20 | $0.07 | Below range |
| Q4 FY2021 | adjusted EPS | $0.43 – $0.45 | $0.45 | Within range |
| Q4 FY2021 | EPS (GAAP) | $0.21 – $0.23 | $0.06 | Below range |
Guidance history
Every forecast Boston Scientific put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Oct 28, 2026 | adjusted EPS | Q4 FY2026 | $0.77 – $0.79 | New |
| Oct 28, 2026 | adjusted EPS | FY2026 | $3.16 – $3.18 | New |
| Oct 28, 2026 | net sales | Q4 FY2026 | -3% – -1% | New |
| Oct 28, 2026 | net sales | Q4 FY2026 | -3% – -1% | New |
| Oct 28, 2026 | net sales growth | FY2026 | +4.25% | New |
| Oct 28, 2026 | net sales growth | FY2026 | +3.75% | New |
| Jul 29, 2026 | adjusted EPS | Q3 FY2026 | $0.80 – $0.82 | New |
| Jul 29, 2026 | adjusted EPS | FY2026 | $3.28 – $3.32 | Lowered |
| Jul 29, 2026 | net sales growth | FY2026 | +5.5% – +6.5% | Lowered |
| Jul 29, 2026 | organic net sales guidance | FY2026 | +5% – +6% | Lowered |
| Jul 29, 2026 | net sales growth | Q3 FY2026 | +3% – +5% | New |
| Jul 29, 2026 | organic net sales guidance | Q3 FY2026 | +3% – +5% | New |
| Apr 22, 2026 | adjusted EPS | FY2026 | $3.34 – $3.41 | Lowered |
| Apr 22, 2026 | adjusted EPS | Q2 FY2026 | $0.82 – $0.84 | New |
| Apr 22, 2026 | net sales growth | Q2 FY2026 | +5.5% – +7.5% | New |
| Apr 22, 2026 | net sales growth | FY2026 | +7% – +8.5% | Lowered |
| Apr 22, 2026 | organic net sales growth | FY2026 | +6.5% – +8% | Lowered |
| Apr 22, 2026 | organic net sales growth | Q2 FY2026 | +5% – +7% | New |
| Feb 4, 2026 | adjusted EPS | Q1 FY2026 | $0.78 – $0.80 | New |
| Feb 4, 2026 | adjusted EPS | FY2026 | $3.43 – $3.49 | New |
| Feb 4, 2026 | net sales growth on a reported basis | FY2026 | +10.5% – +11.5% | New |
| Feb 4, 2026 | organic net sales growth | FY2026 | +10% – +11% | New |
| Feb 4, 2026 | net sales growth on a reported basis | Q1 FY2026 | +10.5% – +12% | New |
| Feb 4, 2026 | organic net sales growth | Q1 FY2026 | +8.5% – +10% | New |
| Oct 22, 2025 | adjusted EPS | Q4 FY2025 | $0.77 – $0.79 | New |
| Oct 22, 2025 | adjusted EPS | FY2025 | $3.02 – $3.04 | Raised |
| Oct 22, 2025 | EPS on a GAAP basis | FY2025 | $1.97 – $2.01 | Raised |
| Oct 22, 2025 | EPS on a GAAP basis | Q4 FY2025 | $0.48 – $0.52 | New |
| Oct 22, 2025 | net sales growth | FY2025 | +20% | Raised |
| Oct 22, 2025 | organic net sales growth | FY2025 | +15.5% | Raised |
| Oct 22, 2025 | net sales growth | Q4 FY2025 | +14.5% – +16.5% | New |
| Oct 22, 2025 | organic net sales growth | Q4 FY2025 | +11% – +13% | New |
| Jul 23, 2025 | adjusted EPS | FY2025 | $2.95 – $2.99 | New |
| Jul 23, 2025 | adjusted EPS | Q3 FY2025 | $0.70 – $0.72 | New |
| Jul 23, 2025 | EPS on a GAAP basis | FY2025 | $1.89 – $1.93 | New |
| Jul 23, 2025 | EPS on a GAAP basis | Q3 FY2025 | $0.44 – $0.46 | New |
| Jul 23, 2025 | net sales growth | FY2025 | +18% – +19% | New |
| Jul 23, 2025 | organic net sales | FY2025 | +14% – +15% | New |
| Jul 23, 2025 | net sales growth | Q3 FY2025 | +17% – +19% | New |
| Jul 23, 2025 | organic net sales | Q3 FY2025 | +12% – +14% | New |
| Apr 23, 2025 | adjusted EPS | Q2 FY2025 | $0.71 – $0.73 | New |
| Apr 23, 2025 | adjusted EPS | FY2025 | $2.87 – $2.94 | Raised |
| Apr 23, 2025 | EPS on a GAAP basis | Q2 FY2025 | $0.45 – $0.47 | New |
| Apr 23, 2025 | EPS on a GAAP basis | FY2025 | $1.86 – $1.93 | Reaffirmed |
| Apr 23, 2025 | net sales growth | Q2 FY2025 | +17.5% – +19.5% | New |
| Apr 23, 2025 | organic net sales growth | Q2 FY2025 | +13% – +15% | New |
| Apr 23, 2025 | net sales growth | FY2025 | +15% – +17% | Raised |
| Apr 23, 2025 | organic net sales growth | FY2025 | +12% – +14% | Raised |
| Feb 5, 2025 | adjusted EPS | Q1 FY2025 | $0.66 – $0.68 | New |
| Feb 5, 2025 | adjusted EPS | FY2025 | $2.80 – $2.87 | New |
| Feb 5, 2025 | EPS on a GAAP basis | Q1 FY2025 | $0.43 – $0.45 | New |
| Feb 5, 2025 | EPS on a GAAP basis | FY2025 | $1.86 – $1.93 | New |
| Feb 5, 2025 | net sales growth | Q1 FY2025 | +17% – +19% | New |
| Feb 5, 2025 | organic net sales growth | Q1 FY2025 | +14% – +16% | New |
| Feb 5, 2025 | net sales growth | FY2025 | +12.5% – +14.5% | New |
| Feb 5, 2025 | organic net sales growth | FY2025 | +10% – +12% | New |
| Oct 23, 2024 | adjusted EPS | Q4 FY2024 | $0.64 – $0.66 | New |
| Oct 23, 2024 | adjusted EPS | FY2024 | $2.45 – $2.47 | Raised |
| Oct 23, 2024 | EPS on a GAAP basis | Q4 FY2024 | $0.41 – $0.43 | New |
| Oct 23, 2024 | EPS on a GAAP basis | FY2024 | $1.28 – $1.30 | Lowered |
| Oct 23, 2024 | net sales growth | Q4 FY2024 | +16.5% – +18.5% | New |
| Oct 23, 2024 | net sales growth | Q4 FY2024 | +14% – +16% | New |
| Oct 23, 2024 | net sales growth | FY2024 | +16.5% | Raised |
| Oct 23, 2024 | net sales growth | FY2024 | +15% | Raised |
| Jul 24, 2024 | adjusted EPS | Q3 FY2024 | $0.57 – $0.59 | New |
| Jul 24, 2024 | adjusted EPS | FY2024 | $2.38 – $2.42 | Raised |
| Jul 24, 2024 | EPS | Q3 FY2024 | $0.36 – $0.38 | New |
| Jul 24, 2024 | EPS | FY2024 | $1.34 – $1.38 | Lowered |
| Jul 24, 2024 | net sales growth | Q3 FY2024 | +13% – +15% | New |
| Jul 24, 2024 | net sales growth | Q3 FY2024 | +13% – +15% | New |
| Jul 24, 2024 | net sales growth | FY2024 | +13.5% – +14.5% | Raised |
| Jul 24, 2024 | net sales growth | FY2024 | +13% – +14% | Raised |
| Apr 24, 2024 | adjusted EPS | Q2 FY2024 | $0.57 – $0.59 | New |
| Apr 24, 2024 | adjusted EPS | FY2024 | $2.29 – $2.34 | Raised |
| Apr 24, 2024 | EPS on a GAAP basis | Q2 FY2024 | $0.35 – $0.37 | New |
| Apr 24, 2024 | EPS on a GAAP basis | FY2024 | $1.43 – $1.48 | Raised |
| Apr 24, 2024 | net sales growth | Q2 FY2024 | +10.5% – +12.5% | New |
| Apr 24, 2024 | organic net sales guidance | Q2 FY2024 | +10% – +12% | New |
| Apr 24, 2024 | net sales growth | FY2024 | +11% – +13% | Raised |
| Apr 24, 2024 | organic net sales guidance | FY2024 | +10% – +12% | Raised |
| Jan 31, 2024 | adjusted EPS | Q1 FY2024 | $0.50 – $0.52 | New |
| Jan 31, 2024 | adjusted EPS | FY2024 | $2.23 – $2.27 | New |
| Jan 31, 2024 | EPS | FY2024 | $1.38 – $1.42 | New |
| Jan 31, 2024 | EPS | Q1 FY2024 | $0.29 – $0.31 | New |
| Jan 31, 2024 | net sales growth | Q1 FY2024 | +7.5% – +9.5% | New |
| Jan 31, 2024 | organic net sales | Q1 FY2024 | +7% – +9% | New |
| Jan 31, 2024 | net sales growth | FY2024 | +8.5% – +9.5% | New |
| Jan 31, 2024 | organic net sales | FY2024 | +8% – +9% | New |
| Oct 26, 2023 | adjusted EPS | FY2023 | $1.99 – $2.02 | Raised |
| Oct 26, 2023 | adjusted EPS | Q4 FY2023 | $0.49 – $0.52 | New |
| Oct 26, 2023 | EPS on a GAAP basis | Q4 FY2023 | $0.26 – $0.30 | New |
| Oct 26, 2023 | EPS on a GAAP basis | FY2023 | $1.00 – $1.04 | Raised |
| Oct 26, 2023 | net sales growth | Q4 FY2023 | +9% – +11% | New |
| Oct 26, 2023 | organic net sales growth | Q4 FY2023 | +8% – +10% | New |
| Oct 26, 2023 | net sales growth | FY2023 | +11% | Narrowed |
| Oct 26, 2023 | organic net sales growth | FY2023 | +11% | Raised |
| Jul 27, 2023 | adjusted EPS | Q3 FY2023 | $0.46 – $0.48 | New |
| Jul 27, 2023 | adjusted EPS | FY2023 | $1.96 – $2.00 | Raised |
| Jul 27, 2023 | EPS on a GAAP basis | Q3 FY2023 | $0.21 – $0.25 | New |
| Jul 27, 2023 | EPS on a GAAP basis | FY2023 | $0.87 – $0.93 | Lowered |
| Jul 27, 2023 | net sales growth | Q3 FY2023 | +8.5% – +10.5% | New |
| Jul 27, 2023 | organic net sales | Q3 FY2023 | +7% – +9% | New |
| Jul 27, 2023 | net sales growth | FY2023 | +10.5% – +11.5% | Raised |
| Jul 27, 2023 | organic net sales | FY2023 | +10% – +11% | Raised |
| Apr 26, 2023 | adjusted EPS | Q2 FY2023 | $0.48 – $0.50 | New |
| Apr 26, 2023 | adjusted EPS | FY2023 | $1.90 – $1.96 | Raised |
| Apr 26, 2023 | EPS on a GAAP basis | Q2 FY2023 | $0.23 – $0.27 | New |
| Apr 26, 2023 | EPS on a GAAP basis | FY2023 | $0.93 – $1.02 | Lowered |
| Apr 26, 2023 | net sales growth | Q2 FY2023 | +6.5% – +8.5% | New |
| Apr 26, 2023 | net sales growth on an organic basis | Q2 FY2023 | +7% – +9% | New |
| Apr 26, 2023 | net sales growth | FY2023 | +8.5% – +10.5% | Raised |
| Apr 26, 2023 | net sales growth on an organic basis | FY2023 | +8% – +10% | Raised |
| Feb 1, 2023 | adjusted EPS | Q1 FY2023 | $0.42 – $0.44 | New |
| Feb 1, 2023 | adjusted EPS | FY2023 | $1.86 – $1.93 | New |
| Feb 1, 2023 | EPS on a GAAP basis | Q1 FY2023 | $0.23 – $0.26 | New |
| Feb 1, 2023 | EPS on a GAAP basis | FY2023 | $1.11 – $1.21 | New |
| Feb 1, 2023 | net sales growth | Q1 FY2023 | +3% – +5% | New |
| Feb 1, 2023 | net sales growth | Q1 FY2023 | +6% – +8% | New |
| Feb 1, 2023 | net sales growth | FY2023 | +5% – +7% | New |
| Feb 1, 2023 | net sales growth | FY2023 | +6% – +8% | New |
| Oct 26, 2022 | adjusted EPS | Q4 FY2022 | $0.45 – $0.48 | New |
| Oct 26, 2022 | adjusted EPS | FY2022 | $1.71 – $1.74 | Lowered |
| Oct 26, 2022 | EPS on a GAAP basis | Q4 FY2022 | $0.23 – $0.28 | New |
| Oct 26, 2022 | EPS on a GAAP basis | FY2022 | $0.57 – $0.63 | Lowered |
| Oct 26, 2022 | net sales growth | Q4 FY2022 | +2% – +4% | New |
| Oct 26, 2022 | organic net sales growth | Q4 FY2022 | +7% – +9% | New |
| Oct 26, 2022 | net sales growth | FY2022 | +6.5% | Lowered |
| Oct 26, 2022 | organic net sales growth | FY2022 | +9% | Raised |
| Jul 27, 2022 | adjusted EPS | Q3 FY2022 | $0.43 – $0.45 | New |
| Jul 27, 2022 | adjusted EPS | FY2022 | $1.74 – $1.77 | Lowered |
| Jul 27, 2022 | EPS on a GAAP basis | Q3 FY2022 | $0.20 – $0.24 | New |
| Jul 27, 2022 | EPS on a GAAP basis | FY2022 | $0.69 – $0.76 | Lowered |
| Jul 27, 2022 | net sales growth | Q3 FY2022 | +6% – +8% | New |
| Jul 27, 2022 | organic net sales growth | Q3 FY2022 | +8% – +10% | New |
| Jul 27, 2022 | net sales growth | FY2022 | +6.5% – +7.5% | Lowered |
| Jul 27, 2022 | organic net sales growth | FY2022 | +8% – +9% | Raised |
| Apr 27, 2022 | adjusted EPS | Q2 FY2022 | $0.41 – $0.43 | New |
| Apr 27, 2022 | adjusted EPS | FY2022 | $1.74 – $1.79 | Raised |
| Apr 27, 2022 | EPS on a GAAP basis | Q2 FY2022 | $0.19 – $0.23 | New |
| Apr 27, 2022 | EPS on a GAAP basis | FY2022 | $0.78 – $0.88 | Lowered |
| Apr 27, 2022 | net sales growth | Q2 FY2022 | +3% – +6% | New |
| Apr 27, 2022 | organic net sales growth | Q2 FY2022 | +3% – +6% | New |
| Apr 27, 2022 | net sales growth | FY2022 | +7% – +9% | Raised |
| Apr 27, 2022 | organic net sales growth | FY2022 | +6.5% – +8.5% | Raised |
| Feb 2, 2022 | adjusted EPS | Q1 FY2022 | $0.38 – $0.40 | New |
| Feb 2, 2022 | adjusted EPS | FY2022 | $1.73 – $1.79 | New |
| Feb 2, 2022 | EPS on a GAAP basis | Q1 FY2022 | $0.16 – $0.20 | New |
| Feb 2, 2022 | EPS on a GAAP basis | FY2022 | $0.94 – $1.04 | New |
| Feb 2, 2022 | organic net sales growth | Q1 FY2022 | +5% – +8% | New |
| Feb 2, 2022 | net sales growth | FY2022 | +6% – +8% | New |
| Feb 2, 2022 | organic net sales growth | FY2022 | +6% – +8% | New |
| Feb 2, 2022 | net sales growth | Q1 FY2022 | +5% – +8% | New |
| Oct 27, 2021 | adjusted EPS | Q4 FY2021 | $0.43 – $0.45 | New |
| Oct 27, 2021 | adjusted EPS | FY2021 | $1.60 – $1.62 | New |
| Oct 27, 2021 | EPS | Q4 FY2021 | $0.21 – $0.23 | New |
| Oct 27, 2021 | EPS | FY2021 | $0.83 – $0.85 | New |
| Oct 27, 2021 | net sales growth | Q4 FY2021 | +13% – +17% | New |
| Oct 27, 2021 | organic net sales growth | Q4 FY2021 | +12% – +16% | New |
| Oct 27, 2021 | net sales growth | FY2021 | +19% – +20% | New |
| Oct 27, 2021 | organic net sales growth | FY2021 | +18% – +19% | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Boston Scientific filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating OfficerNews
- Results
- News
- News
- Results
- News
- News
- Update
- Results
- Scientific’s cardiovascular portfolio and further address increasing prevalence of vascular diseasesUpdate
- Update
- Results
- Results
- News